Aspirin 75mg dispersible tablets

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktif bileşen:

Aspirin

Mevcut itibaren:

Bristol Laboratories Ltd

ATC kodu:

B01AC06

INN (International Adı):

Aspirin

Doz:

75mg

Farmasötik formu:

Dispersible tablet

Uygulama yolu:

Oral

Sınıf:

No Controlled Drug Status

Reçete türü:

Valid as a prescribable product

Ürün özeti:

BNF: 02090000; GTIN: 5060013941344 5060013941283

Bilgilendirme broşürü

Dispersible Aspirin 75 mg
Tablets 0155 Insert
SAME SIZE ARTWORK
430 x 130 mm
Front
30 mm
430 mm
130 mm
IXXXXXX
Package Leaflet: Information for the user
DISPERSIBLE ASPIRIN 75MG TABLETS
Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor, or pharmacist or
nurse.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the
same as yours.
•
If you get any side effects, talk to your your doctor, or pharmacist
or nurse. This includes any possible side effects not listed in this
leaflet. See section 4.
What is in this leaflet:
1. What Aspirin is and what it is used for
2. What you need to know before you take Aspirin
3. How to take Aspirin
4. Possible side effects
5. How to store Aspirin
6. Contents of the pack and other information
1. What Aspirin is and what it is used for
•
Each tablet contains the active ingredient Aspirin 75 mg of medicines
called antiplatelet agents that help prevent your blood cells
sticking together and forming a blood clot
•
Aspirin are principally used to prevent blood clots forming following
a heart attack or stroke or to help prevent heart attacks and
strokes in patients who have previously suffered from these
conditions. They may have been prescribed for you if you have
recently had by-pass surgery.
2. What you need to know before you take Aspirin
Do not take this medicine if you:
•
are allergic to acetylsalicylic acid or any of the ingredients in this
medicine (see section 6)
•
are allergic to other salicylates or nonsteroidal anti-inflammatory
drugs (NSAIDs). NSAIDs are often used for arthritis or
rheumatism and pain
•
have had an asthma attack or swelling of some parts of the body e.g.
face, lips, throat or tongue (angioedema) after taking salicylates
or NSAIDs
•
currently have or have ever had an ulcer in your stomach

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Dispersible Aspirin 75 mg Tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains aspirin 75 mg as the active ingredient.
Excipients with known effect: Also contains lactose monohydrate 27.5
mg
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Dispersible Tablets
White, flat tablets, debossed on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the secondary prevention of thrombotic cerebrovascular or
cardiovascular disease
and following by –pass surgery.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
For the management of cardiovascular or cerebrovascular disease:
The advice of a doctor should be sought before commencing therapy for
the first time.
The usual dosage, for long term use, is 75-150mg once daily. In some
circumstances a
higher dose may be appropriate, especially in the short term, and up
to 300mg a day
may be used on the advice of a doctor. In general, acetylsalicylic
acids should be used
with caution in elderly patients who are more prone to adverse events.
The usual adult
dose is recommended in the absence of severe renal or hepatic
insufficiency (see
sections 4.3 and 4.4). Treatment should be reviewed at regular
intervals.
CHILDREN:
Aspirin 75mg Tablets is not indicated for use in children and young
people less than
16 years of age (see 'Special Warnings and Precautions for Use').
Method of administration
Oral administration, after dissolution in water.
4.3
CONTRAINDICATIONS
•
Hypersensitivity to salicylic acid compounds or prostaglandin
synthetase inhibitors (e.g.
certain asthma patients who may suffer an attack or faint and certain
patients who may suffer
from bronchospasm, rhinitis and urticaria) and to any of the
excipients listed in section 6.1
•
Active, or history of recurrent peptic ulcer and/or gastric/intestinal
haemorrhage, or other
kinds of bleeding such as cerebrovascular haemorrhages.
•
Haemorrhagic diathesis; coagulation disorders such as haemophi